You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動丨歌禮制藥大漲超25%,自主研發的ASC30迎好消息
格隆匯 02-20 09:32
歌禮制藥-B(1672.HK)高開高走,盤初拉昇超25%,報6港元,股價創2022年4月以來新高。消息面上,公司宣佈小分子口服GLP-1R激動劑ASC30在美國開展的每日一次口服片用於治療肥胖症患者(體重指數(BMI):30-40kg/m2)的隨機、雙盲、安慰劑對照的Ib期多劑量遞增(MAD)研究(NCT06680440)前兩個隊列取得積極期中結果。據悉,由歌禮自主研發的ASC30是首款也是唯一一款既可每日一次口服也可每月一次皮下注射的用於治療肥胖症的小分子GLP-1受體(GLP-1R)激動劑。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account